Although Sarepta Therapeutics Inc (SRPT) is up over 18.6% in the past four weeks, investors may be concerned. After all, SRPT is now in overbought territory, at least when looking at its RSI value of 70.7. If that wasn’t enough, investors should also note that Sarepta possesses a Zacks Rank #4 (Sell), so if analyst perception is any guide, we could witness a slump in SRPT shares before too long.
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment